Blood Pressure and Angina-Related Health Status During Benidipine Therapy: A Multicenter Real-World Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ülgen Kunak Ayşegül, Kunak Tolga, Aydın Ertan, Sinan Ümit Yaşar, Elmas Ali Nizami, Uyan Umut, Ekici Berkay, Aslan Onur, Arık Baran, Korkmaz Kübra, Doğduş Mustafa, Kaya Ahmet Ferhat, Ülvan Nedret, Çalışkan Serhat, Öztürk Berkant, Kök Zafer, Kerkütlüoğlu Murat, Kış Mehmet, İnci Sinan, Huyut Mustafa Ahmet, Hekimsoy Vedat, Yeşil Emrah, Bekler Özkan, Tekeli Şengül Sebahat, Kaya Emrah, Demirkıran Aykut, Ömür Sefa Erdi, Durmuş Halil İbrahim, Koç Şahbender, Aydın Saadet, Katkat Fahrettin, Kümet Ömer, Küçükukur Murat, Oktay Aysu, Ertürk Mehmet, Şen Taner, Şentürk Nurcemal, Solmaz Hatice, Bekar Lütfü, Kayhan Özkan, Ildızlı Demirbaş Müge, Toprak Kenan, Kanat Sedat, Conkbayır Cenk, Akgümüş Alkame, Er Fahri, Bedir Ömer, Duz Ramazan, Narçiçeği Harun Recep, Deniz Yasin, Bostanoğlu Nezihe İlknur, Zoghi Mehdi, Ergene Asım Oktay
Аннотация
Background: Benidipine is a long-acting calcium channel blocker used for the treatment of hypertension and chronic coronary syndrome. Although it effectively lowers blood pressure (BP), the relationship between BP reduction and improvement in angina-related health status during benidipine therapy remains uncertain. This study evaluated changes in BP and patient-reported angina-related health status in a large real-world cohort. Methods: This prospective, multicenter, observational cohort study included 1659 patients with hypertension and/or chronic coronary syndrome who underwent baseline clinical assessment before initiation of benidipine therapy and were reassessed after 3 months. Changes in systolic and diastolic BP and Seattle Angina Questionnaire-7 (SAQ-7) scores were evaluated. Multivariable linear regression analyses were performed to identify predictors of BP reduction and symptomatic improvement. A propensity score-matched analysis according to coronary artery disease (CAD) status was conducted to further explore differences in treatment response. Results: The mean age was 62.2 ± 12.2 years, and 54.0% of participants were women. Systolic BP decreased by 13.8 mmHg and diastolic BP by 6.7 mmHg (both p < 0.001). Mean SAQ-7 score increased by 8.1 points (p < 0.001), exceeding the established threshold for clinically meaningful improvement. Baseline SAQ-7 score showed the strongest association with change in SAQ-7, whereas baseline systolic BP was the strongest predictor of BP reduction. The correlation between changes in systolic BP and SAQ-7 was weak (r = 0.058, p = 0.023). In the propensity score-matched cohort (n = 732), BP reduction was similar regardless of CAD status, whereas improvement in SAQ-7 was greater in patients without obstructive CAD. Conclusions: In this multicenter real-world cohort, benidipine therapy was associated with significant BP reduction and clinically meaningful improvement in angina-related health status over 3 months. Symptomatic improvement showed only a weak association with BP reduction. These findings should be interpreted within the limitations of an observational study and warrant confirmation in controlled comparative studies.